Literature DB >> 31099271

Moving beyond sodium valproate: choosing the right anti-epileptic drug in children.

Ganna Balagura1,2, Giulia Iapadre3, Alberto Verrotti3, Pasquale Striano1,2.   

Abstract

Introduction: Sodium valproate is a widely used anti-epileptic drug with a broad spectrum of activity and mechanism of action. It has consequently been the first-line drug for most seizure types in children for the past fifty years. A wide range of side effects come along with these exceptional properties, including teratogenicity and neuro-cognitive impairments in offspring. Therefore, epilepsy treatment in children and adolescents should be reassessed in light of newer antiepileptic drugs as well as a more targeted-approach with older drugs. Areas covered: The authors review the main concerns of valproate use in terms of adverse effects on different systems and drug interactions. The current alternatives to valproate in absence, myoclonic, tonic-clonic and focal onset seizures in children/adolescents are also reviewed. Expert opinion: There are several issues that research should address in antiepileptic therapy and in clinical studies with children, given the peculiarity of this population. Future perspectives in epilepsy therapy should now lead towards an individualized treatment.

Entities:  

Keywords:  Epilepsy; adverse effects; antiseizure drugs; children; therapy; valproate

Mesh:

Substances:

Year:  2019        PMID: 31099271     DOI: 10.1080/14656566.2019.1617850

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

Review 1.  Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

2.  Influence of Different Antiepileptic Drugs on Blood Ammonia and Homocysteine Levels in Children with Epilepsy.

Authors:  Meng Sun; Ran Zhou; Xin Wang; Yaying Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-04       Impact factor: 2.629

3.  Evaluation of the Levetiracetam treatment on reduction of epileptic discharges in electroencephalogram in children with epilepsy.

Authors:  Afshin Fayyazi; Mohammad Hossein Ebrahimi; Ghodratollah Roshanaei; Hassan Bazmamoun
Journal:  Iran J Child Neurol       Date:  2021

4.  Valproate and Short-Chain Fatty Acids Activate Transcription of the Human Vitamin D Receptor Gene through a Proximal GC-Rich DNA Region Containing Two Putative Sp1 Binding Sites.

Authors:  Marta Moreno-Torres; Carla Guzmán; Petar D Petrov; Ramiro Jover
Journal:  Nutrients       Date:  2022-06-28       Impact factor: 6.706

Review 5.  Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.

Authors:  Adam Strzelczyk; Susanne Schubert-Bast
Journal:  CNS Drugs       Date:  2022-10-04       Impact factor: 6.497

6.  Comparison of the Therapeutic Effects of Sodium Valproate and Levetiracetam on Pediatric Epilepsy and the Effects of Nerve Growth Factor and γ-Aminobutyric Acid.

Authors:  Min Chen; Yazhou Jiang; Li Ma; Xuedian Zhou; Nuan Wang
Journal:  Iran J Public Health       Date:  2021-03       Impact factor: 1.429

7.  Sodium Valproate Combined With Topiramate vs. Sodium Valproate Alone for Refractory Epilepsy: A Systematic Review and Meta-Analysis.

Authors:  Zhen-Ye Ji; Yi-Qian Huang; Wen-Zhen He
Journal:  Front Neurol       Date:  2022-01-05       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.